Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemical...

Descripción completa

Detalles Bibliográficos
Autores principales: Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/
https://www.ncbi.nlm.nih.gov/pubmed/32257197
http://dx.doi.org/10.3892/mco.2020.2014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/
https://www.ncbi.nlm.nih.gov/pubmed/32257197
http://dx.doi.org/10.3892/mco.2020.2014

Ejemplares similares